Evidence map›Paper›PMID 25829399›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015

Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String".

Lisa M Rimsza

Abstract readComment
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Lisa M RimszaDepartment of Pathology, University of Arizona, Tucson, Arizona. lrimsza@email.arizona.edu.

Funding

Molecular Diagnosis and Prognosis in Aggressive LymphomaU01CA157581 · NCI · UNIVERSITY OF ARIZONA · PI RIMSZA, LISA · 2011 to 2015
$3.1M
NCI NIH HHS U01 CA157581NCI NIH HHS U01CA157581
6 · The paper itself

Abstract

Molecular classification of diffuse large B-cell lymphoma (DLBCL) is a critical biologic, prognostic, and predictive distinction. Since the discovery of two molecular types of DLBCL in otherwise morphologically indistinguishable cases, numerous methodologies for making this distinction have been published. A method and technical platform may now be reaching consensus.

Indexed as

Biomarkers, TumorGene Expression ProfilingHumansLymphoma, Large B-Cell, DiffuseBiomarkers, Tumor

Identifiers

PMID25829399
PMCPMC4433835

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.